An amyloid-β protofibril-selective antibody prevents amyloid formation in a mouse model of Alzheimer's disease

Neurobiology of Disease

Volumn 36, Issue 3, 2009, Pages 425-434

  Lord, Anna ^a   Gumucio, Astrid ^a   Englund, Hillevi ^a   Sehlin, Dag ^a   Sundquist, Valentina Screpanti ^b   Söderberg, Linda ^b   Möller, Christer ^b   Gellerfors, Pär ^b   Lannfelt, Lars ^a   Pettersson, Frida Ekholm ^a   Nilsson, Lars N G ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b BioArctic Neuroscience   (Sweden)

Author keywords

Alzheimer's disease; Immunotherapy; Intraneuronal; Monoclonal antibody; Soluble amyloid ; Transgenic mice

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 158; PLACEBO; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROTECTION; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG TARGETING; GENE MUTATION; IMMUNOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN TARGETING; RAT; SENILE PLAQUE;

AGING; ALZHEIMER DISEASE; AMYLOID; AMYLOID BETA-PROTEIN; ANIMALS; ANTIBODIES, MONOCLONAL; BRAIN; DISEASE MODELS, ANIMAL; HUMANS; IMMUNIZATION, PASSIVE; KINETICS; LEARNING; MICE; MICE, TRANSGENIC; PEPTIDE FRAGMENTS; PROTEIN MULTIMERIZATION; SENILE PLAQUES; SPACE PERCEPTION;

EID: 70350324013     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2009.08.007     Document Type: Article

References (50)

1. Bacskai B.J., Kajdasz S.T., McLellan M.E., Games D., Seubert P., Schenk D., and Hyman B.T. Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy. J. Neurosci. 22 18 (2002) 7873-7878
2. Bard F., Barbour R., Cannon C., Carretto R., Fox M., Games D., Guido T., Hoenow K., Hu K., Johnson-Wood K., Khan K., Kholodenko D., Lee C., Lee M., Motter R., Nguyen M., Reed A., Schenk D., Tang P., Vasquez N., Seubert P., and Yednock T. Epitope and isotype specificities of antibodies to beta-amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc. Natl. Acad. Sci. U. S. A. 100 4 (2003) 2023-2028
3. Bard F., Cannon C., Barbour R., Burke R.L., Games D., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Lieberburg I., Motter R., Nguyen M., Soriano F., Vasquez N., Weiss K., Welch B., Seubert P., Schenk D., and Yednock T. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 6 8 (2000) 916-919
4. Billings L.M., Oddo S., Green K.N., McGaugh J.L., and Laferla F.M. Intraneuronal abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron 45 5 (2005) 675-688
5. Blennow K., de Leon M.J., and Zetterberg H. Alzheimer's disease. Lancet 368 9533 (2006) 387-403
6. Bussiere T., Bard F., Barbour R., Grajeda H., Guido T., Khan K., Schenk D., Games D., Seubert P., and Buttini M. Morphological characterization of Thioflavin-S-positive amyloid plaques in transgenic Alzheimer mice and effect of passive Abeta immunotherapy on their clearance. Am. J. Pathol. 165 3 (2004) 987-995
7. Chauhan N.B., and Siegel G.J. Efficacy of anti-Abeta antibody isotypes used for intracerebroventricular immunization in TgCRND8. Neurosci. Lett. 375 3 (2005) 143-147
8. Chen G., Chen K.S., Knox J., Inglis J., Bernard A., Martin S.J., Justice A., McConlogue L., Games D., Freedman S.B., and Morris R.G. A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease. Nature 408 6815 (2000) 975-979
9. Cirrito J.R., May P.C., O'Dell M.A., Taylor J.W., Parsadanian M., Cramer J.W., Audia J.E., Nissen J.S., Bales K.R., Paul S.M., DeMattos R.B., and Holtzman D.M. In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life. J. Neurosci. 23 26 (2003) 8844-8853
10. -/- knock-out mice. J. Neurosci. 23 24 (2003) 8532-8538
11. DeMattos R.B., Bales K.R., Cummins D.J., Dodart J.C., Paul S.M., and Holtzman D.M. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 98 15 (2001) 8850-8855
12. Dodart J.C., Bales K.R., Gannon K.S., Greene S.J., DeMattos R.B., Mathis C., DeLong C.A., Wu S., Wu X., Holtzman D.M., and Paul S.M. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat. Neurosci. 5 5 (2002) 452-457
13. Englund H., Sehlin D., Johansson A.S., Nilsson L.N., Gellerfors P., Paulie S., Lannfelt L., and Pettersson F.E. Sensitive ELISA detection of amyloid-beta protofibrils in biological samples. J. Neurochem. 103 1 (2007) 334-345
14. Gilman S., Koller M., Black R.S., Jenkins L., Griffith S.G., Fox N.C., Eisner L., Kirby L., Rovira M.B., Forette F., and Orgogozo J.M. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64 9 (2005) 1553-1562
15. Haass C., and Selkoe D.J. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat. Rev. Mol. Cell. Biol. 8 2 (2007) 101-112
16. Hardy J., and Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297 5580 (2002) 353-356
17. Harper J.D., Wong S.S., Lieber C.M., and Lansbury P.T. Observation of metastable Abeta amyloid protofibrils by atomic force microscopy. Chem. Biol. 4 2 (1997) 119-125
18. Hartley D.M., Walsh D.M., Ye C.P., Diehl T., Vasquez S., Vassilev P.M., Teplow D.B., and Selkoe D.J. Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J. Neurosci. 19 20 (1999) 8876-8884
19. Hock C., Konietzko U., Streffer J.R., Tracy J., Signorell A., Muller-Tillmanns B., Lemke U., Henke K., Moritz E., Garcia E., Wollmer M.A., Umbricht D., de Quervain D.J., Hofmann M., Maddalena A., Papassotiropoulos A., and Nitsch R.M. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron 38 4 (2003) 547-554
20. Holmes C., Boche D., Wilkinson D., Yadegarfar G., Hopkins V., Bayer A., Jones R.W., Bullock R., Love S., Neal J.W., Zotova E., and Nicoll J.A. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 372 9634 (2008) 216-223
21. Kamenetz F., Tomita T., Hsieh H., Seabrook G., Borchelt D., Iwatsubo T., Sisodia S., and Malinow R. APP processing and synaptic function. Neuron 37 6 (2003) 925-937
22. Karlnoski R.A., Rosenthal A., Alamed J., Ronan V., Gordon M.N., Gottschall P.E., Grimm J., Pons J., and Morgan D. Deglycosylated anti-Abeta antibody dose-response effects on pathology and memory in APP transgenic mice. J. Neuroimmune Pharmacol. 3 3 (2008) 187-197
23. Lee E.B., Leng L.Z., Zhang B., Kwong L., Trojanowski J.Q., Abel T., and Lee V.M. Targeting amyloid-beta peptide (abeta) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in abeta precursor protein (APP) transgenic mice. J. Biol. Chem. 281 7 (2006) 4292-4299
24. Legleiter J., Czilli D.L., Gitter B., DeMattos R.B., Holtzman D.M., and Kowalewski T. Effect of different anti-Abeta antibodies on Abeta fibrillogenesis as assessed by atomic force microscopy. J. Mol. Biol. 335 4 (2004) 997-1006
25. LeVine III H. Thioflavine T interaction with synthetic Alzheimer's disease beta-amyloid peptides: detection of amyloid aggregation in solution. Protein Sci. 2 3 (1993) 404-410
26. Levites Y., Das P., Price R.W., Rochette M.J., Kostura L.A., McGowan E.M., Murphy M.P., and Golde T.E. Anti-Abeta(42)- and anti-Abeta(40)-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model. J. Clin. Invest. 116 1 (2006) 193-201
27. Lippa C.F., Nee L.E., Mori H., and St George-Hyslop P. Abeta-42 deposition precedes other changes in PS-1 Alzheimer's disease. Lancet 352 9134 (1998) 1117-1118
28. Lord A., Englund H., Soderberg L., Tucker S., Clausen F., Hillered L., Gordon M., Morgan D., Lannfelt L., Pettersson F.E., and Nilsson L.N. Amyloid-beta protofibril levels correlate with spatial learning in Arctic Alzheimer's disease transgenic mice. FEBS J. 276 4 (2009) 995-1006
29. Lord A., Kalimo H., Eckman C., Zhang X.Q., Lannfelt L., and Nilsson L.N. The Arctic Alzheimer mutation facilitates early intraneuronal Abeta aggregation and senile plaque formation in transgenic mice. Neurobiol. Aging 27 1 (2006) 67-77
30. Lue L.F., Kuo Y.M., Roher A.E., Brachova L., Shen Y., Sue L., Beach T., Kurth J.H., Rydel R.E., and Rogers J. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am. J. Pathol. 155 3 (1999) 853-862
31. McLean C.A., Cherny R.A., Fraser F.W., Fuller S.J., Smith M.J., Beyreuther K., Bush A.I., and Masters C.L. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann. Neurol. 46 6 (1999) 860-866
32. Monsonego A., Imitola J., Zota V., Oida T., and Weiner H.L. Microglia-mediated nitric oxide cytotoxicity of T cells following amyloid beta-peptide presentation to Th1 cells. J. Immunol. 171 5 (2003) 2216-2224
33. Morgan D., Diamond D.M., Gottschall P.E., Ugen K.E., Dickey C., Hardy J., Duff K., Jantzen P., DiCarlo G., Wilcock D., Connor K., Hatcher J., Hope C., Gordon M., and Arendash G.W. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408 6815 (2000) 982-985
34. Nilsberth C., Westlind-Danielsson A., Eckman C.B., Condron M.M., Axelman K., Forsell C., Stenh C., Luthman J., Teplow D.B., Younkin S.G., Naslund J., and Lannfelt L. The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation. Nat. Neurosci. 4 9 (2001) 887-893
35. Näslund J., Haroutunian V., Mohs R., Davis K.L., Davies P., Greengard P., and Buxbaum J.D. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. Jama 283 12 (2000) 1571-1577
36. Oddo S., Billings L., Kesslak J.P., Cribbs D.H., and LaFerla F.M. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 43 3 (2004) 321-332
37. Oddo S., Caccamo A., Smith I.F., Green K.N., and Laferla F.M. A dynamic relationship between intracellular and extracellular pools of A{beta}. Am. J. Pathol. 168 1 (2006) 184-194
38. Oddo S., Vasilevko V., Caccamo A., Kitazawa M., Cribbs D.H., and LaFerla F.M. Reduction of soluble Abeta and tau, but not soluble Abeta alone, ameliorates cognitive decline in transgenic mice with plaques and tangles. J. Biol. Chem. 281 51 (2006) 39413-39423
39. Orgogozo J.M., Gilman S., Dartigues J.F., Laurent B., Puel M., Kirby L.C., Jouanny P., Dubois B., Eisner L., Flitman S., Michel B.F., Boada M., Frank A., and Hock C. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61 1 (2003) 46-54
40. Philipson, O., Hammarstrom, P., Nilsson, K.P., Portelius, E., Olofsson, T., Ingelsson, M., Hyman, B.T., Blennow, K., Lannfelt, L., Kalimo, H., Nilsson, L. N., 2009. A highly insoluble state of Abeta similar to that of Alzheimer's disease brain is found in Arctic APP transgenic mice. Neurobiol. Aging. 30 (9), 1393-1405.
41. Sahlin C., Lord A., Magnusson K., Englund H., Almeida C.G., Greengard P., Nyberg F., Gouras G.K., Lannfelt L., and Nilsson L.N. The Arctic Alzheimer mutation favors intracellular amyloid-beta production by making amyloid precursor protein less available to alpha-secretase. J. Neurochem. 101 3 (2007) 854-862
42. Savage M.J., Trusko S.P., Howland D.S., Pinsker L.R., Mistretta S., Reaume A.G., Greenberg B.D., Siman R., and Scott R.W. Turnover of amyloid beta-protein in mouse brain and acute reduction of its level by phorbol ester. J. Neurosci. 18 5 (1998) 1743-1752
43. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Liao Z., Lieberburg I., Motter R., Mutter L., Soriano F., Shopp G., Vasquez N., Vandevert C., Walker S., Wogulis M., Yednock T., Games D., and Seubert P. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400 6740 (1999) 173-177
44. Schroeter S., Khan K., Barbour R., Doan M., Chen M., Guido T., Gill D., Basi G., Schenk D., Seubert P., and Games D. Immunotherapy reduces vascular amyloid-beta in PDAPP mice. J. Neurosci. 28 27 (2008) 6787-6793
45. Seubert P., Vigo-Pelfrey C., Esch F., Lee M., Dovey H., Davis D., Sinha S., Schlossmacher M., Whaley J., Swindlehurst C., et al. Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature 359 6393 (1992) 325-327
46. Solomon B., Koppel R., Hanan E., and Katzav T. Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide. Proc. Natl. Acad. Sci. U. S. A. 93 1 (1996) 452-455
47. Stenh C., Englund H., Lord A., Johansson A.S., Almeida C.G., Gellerfors P., Greengard P., Gouras G.K., Lannfelt L., and Nilsson L.N. Amyloid-beta oligomers are inefficiently measured by enzyme-linked immunosorbent assay. Ann. Neurol. 58 1 (2005) 147-150
48. Tampellini D., Magrane J., Takahashi R.H., Li F., Lin M.T., Almeida C.G., and Gouras G.K. Internalized antibodies to the Abeta domain of APP reduce neuronal Abeta and protect against synaptic alterations. J. Biol. Chem. 282 26 (2007) 18895-18906
49. Tucker S.M., Borchelt D.R., and Troncoso J.C. Limited clearance of pre-existing amyloid plaques after intracerebral injection of Abeta antibodies in two mouse models of Alzheimer disease. J. Neuropathol. Exp. Neurol. 67 1 (2008) 30-40
50. Vellas B., Black R., Thal L.J., Fox N.C., Daniels M., McLennan G., Tompkins C., Leibman C., Pomfret M., and Grundman M. Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders. Curr. Alzheimer. Res. 6 2 (2009) 144-151